I. COMPLETED MERGERS AND ACQUISITIONS

Company Acquired
(Country; Symbol)

Acquired By
Or Merged With (Country; Symbol)

Date Announced

Date Completed

Value
(M)***

Terms/Details


Asys Hitech
GmbH
(Austria)*

Harvard Biosciences Inc. (HBIO)

12/7

12/7

ND

Harvard Bioscience acquired Asys, which should add about $1.5M to $2M in revenue for the company in 2002

Atlantic Stem
Cells Inc.*

Anthrogenesis Corp.*

12/6

12/6

ND

Anthrogenesis acquired Atlantic Stem Cells for an undisclosed amount

Aviron Inc.
(AVIR)

MedImmune Inc. (MEDI)

12/3

1/16

$1.5B

MedImmune acquired Aviron in a $1.5B merger; each Aviron share translates into 1.075 shares of MedImmune

Biosonix Ltd.
(Israel)*

Neoprobe Corp. (OTC BB:NEOP)

9/7

12/11

$3.4

Neoprobe acquired Biosonix by issuing about 9.7M shares for all of Biosonix's outstanding shares; the merger is valued at about $3.4M

Bristol-Myers
Squibb Pharma
Research Labs LLC
(unit of Bristol-Myers Squibb Co.; NYSE:BMY)

Deltagen Inc.
(DGEN)

2/11

2/19

$23.5

Deltagen paid about $23.5M in stock to acquire the Bristol-Myers unit

Cartesian Technologies
Inc.*

Genomic Solutions Inc. (GNSL)

9/7

12/20

$16

Genomic Solutions acquired Cartesian by issuing 6.8M shares and spending $2.5M in cash

Cell-Matrix
Inc.*

CancerVax
Corp.*

1/9

1/18

ND

CancerVax acquired Cell-Matrix through stock and assumption of debt; terms were not disclosed

Corporate
Technology
Development
Inc.*

Endorex Corp. (AMEX:DOR)

8/1

12/3

$10.6

Endorex acquired all of the outstanding capital stock of CTD in a stock-for-stock merger; Endorex issued about 9.4M shares

DakDak
Photoaging Technologies
Inc.*

Charles River Laboratories Inc. (subsidiary of Charles River Laboratories International Inc.; NYSE:CRL)

1/14

1/14

$1

Charles River acquired DakDak for $1M in cash; an additional $2M in cash may be paid over three years for milestone achievements

Enzyme Bio-
Systems Ltd.
(unit
of Corn Products International; NYSE:CPO)

Genencor International Inc. (GCOR)

2/5

2/5

$30

Genencor acquired Enzyme BioSystems for about $30M in cash plus working capital

Group Lafon
(France)*

Cephalon Inc. (CEPH)

12/3

12/28

$450

Cephalon acquired Group Lafon for $450M in cash

Lifecodes
orp.*

Orchid BioSciences Inc. (ORCH)

10/1

12/6

$12.7

Orchid acquired Lifecodes for $12.7M in a stock-for-stock transaction under which Lifecodes' shareholders received about 6.6M shares

Matrix Pharmaceuticals Inc. (MATX)

Chiron Corp.
(CHIR)

1/7

2/20

$50.2

Chiron completed a cash tender offer for all of the outstanding common stock of Matrix; it tendered about 22.7M shares at $2.21 per share, valuing the merger at about $50.2M

Melacure
Therapeutics
AB
(Sweden)*

BioFactor Therapeutics AB (Sweden)*

1/17

1/17

ND

The companies merged and will be called Melacure Therapeutics AB, based in Uppsala; terms were not disclosed, but the companies' main shareholders are committing an additional SEK155M (US$15.5M) in equity funding to the merged entity

NetGenics
Inc.*

LION bioscience AG (Germany; LEON)

1/15

1/31

$17.6

LION bought NetGenics in a stock deal totaling about $17.6M; LION issued about 1.12M LION shares

NZ Corp.*

Lipid Sciences
Inc.*

11/30

11/30

ND

The companies merged and the combined company will be called Lipid Sciences Inc.; it will trade under the LIPD symbol on Nasdaq

Osteopharm
Inc.
(subsidiary of
GenSci Regeneration Sciences Inc.; Canada; TSE:GNS)

Charterbridge Holdings Ltd.*

1/7

12/15/01

ND

Charterbridge acquired Osteopharm on Dec. 15, but the companies did not announce it until Jan. 7; the acquisition involved cash, a note and a royalty interest in future Osteopharm products

Pathagon
Inc.*

Bioenvision Inc. (OTC BB:BIOV)

11/30

2/4

ND

Bioenvision acquired Pathagon for an undisclosed amount

PrimeCyte
Inc.*

Signature BioScience Inc.*

1/8

2/6

$20

Signature acquired PrimeCyte in a stock deal valued at between $10M and $20M

The Intergen
Co.*

Serologicals Corp. (SERO)

11/6

12/14

$45

Serologicals acquired The Intergen Co. for $45M in cash, less the amount necessary to complete the expansion of Intergen's Toronto manufacturing facility

Vaxis Therapeutics Corp. (Canada)*

Cellegy Pharmaceuticals
Inc.
(CLGY)

11/29

11/29

$4

Cellegy acquired Vaxis for $4M payable in Cellegy stock plus potential earnout payments over a seven-year period

Vysis Inc.
(VYSI)

Abbott Laboratories (NYSE:ABT)

10/24

11/30

$355

Abbott acquired Vysis in a cash tender offer worth about $355M

Waratah Pharmaceuticals Inc. (Canada; CDNX:WAR)

Transition Therapeutics
Inc.
(Canada; CDNX:TTH)

1/14

1/15

ND

The companies merged; Waratah share-holders will receive 0.8333 common shares for each share of Waratah held; the combined company will retain the name Transition Therapeutics Inc.; the number of shares issued was not disclosed

II. PENDING MERGERS AND ACQUISITIONS

Company
To Be Acquired (Country; Symbol)

Acquiring Company (Country; Symbol)

Date Announced

Expected Completion

Value
(M)***

Terms/Details


COR Thera-
peutics Inc.
(CORR)

Millennium Pharmaceuticals Inc. (MLNM)

12/6

1Q:02

$2B

Millennium plans to acquire COR in a stock exchange worth $2B; COR shareholders will receive 0.9873 shares of Millennium stock for each COR share

Digene Corp. (DIGE)

Cytyc Corp.
(CYTC)

2/19

2Q:02

$554

Cytyc plans to acquire Digene by issuing 23M shares of common stock and paying $76.9M in cash for all outstanding equity of Digene

Drug Royalty
Corp. Inc.
(Canada; TSE:
DRI)

Cambridge Antibody Technology plc (UK; CATG; LSE:CAT)

1/17

ND

C$126 (US$78)

CAT will make an offer by way of a takeover bid for all of the issued shares of DRC, a deal estimated at US$78M

Genomica Corp. (GNOM)

Exelixis Inc.
(EXEL)

11/19

4Q:01

$110

Exelixis plans to buy Genomica for $110M in a stock-for-stock transaction; Genomica will become a wholly owned subsidiary of Exelixis

Oligonucleotides Division of Genset
SA
(France; GENXY)

Proligo Division of Degussa AG (Germany)*

2/21

1Q:02

EUR25 (US$21.8)

Proligo will purchase the division from Genset with Genset retaining a minority interest in certain Asian subsidiaries

Global Genomics Capital Inc.*

CytRx Corp.
(CYTR)

2/11

ND

$6.28

CytRx plans to merge with Global Genomics in a deal valued at $6.28M; CytRx will acquire all outstanding shares and rights to acquire shares of capital stock of Global Genomics by issuing a maximum of 9.963M shares of its common stock

Glyko Biomed-
ical Ltd.
(Canada;
OTC BB:GLYK; TSE:GBL)

BioMarin Pharmaceutical Inc. (BMRN)

2/7

ND

ND

BioMarin plans to acquire all of the outstanding shares of Glyko; Glyko's common shareholders will be entitled to receive 11.37M shares of BioMarin

Immunex Corp.
(IMNX)

Amgen Inc.
(AMGN)

12/17

ND

$16B

Amgen intends to acquire Immunex by exchanging each Immunex share for 0.44 shares of Amgen, plus $4.50 in cash per share; Amgen's shareholders will own about 81% of the combined company

MediChem Life Sciences Inc. (MCLS)

DeCode genetics Inc. (DCGN)

1/8

2Q:02

$83.6

DeCode is buying MediChem in a stock swap worth about $83.6M; MediChem's shareholders will receive 0.3099 shares of newly issued DeCode stock for each share of MediChem

Paralex Inc.*

Cardiome Pharma Corp. (Canada; TSE:COM)

12/21

1Q:02

C$20 (US
$12.61)

Cardiome plans to acquire Paralex in exchange for 33.3M Cardiome shares, valued at about C$20M (US$12.61M)

Point Thera-
peutics Inc.*

HMSR Inc. (OTC BB:HMSR)

11/15

1Q:02

ND

HMSR plans to merge with Point Therapeutics, with each outstanding share of Point being converted into the right to receive about 37.4 shares of HMSR common stock; Point will become a wholly owned subsidiary of HMSR

Synapse Technologies
Inc.
(Canada)*

BioMarin Pharmaceutical Inc. (BMRN)

1/14

ND

$10.2

BioMarin plans to buy Synapse for about $10.18M by exchanging 885,275 shares of its common stock; BioMarin also will make payments of up to $5.1M in either cash or stock upon reaching certain milestones

Biopool hemostasis division of Xtrana Inc. (XTRN)

Trinity Biotech plc (Ireland; TRIB)

11/14**

ND

US
$6.25

Trinity is acquiring the assets and goodwill of the Biopool hemostasis division of Xtrana in a US$6.25M cash deal, comprising a US$3.6M payment up front and additional payments over 36 months

III. TERMINATED MERGERS AND ACQUISITIONS

Company
To Be Acquired** (Country; Symbol)

Acquiring Company (Country; Symbol)

Date Announced

Termination Date

Value
(M)***

Terms/Details


Eos Biotechnology Inc.*

Pharmacopeia Inc. (PCOP)

8/22

1/18

$197

Pharmacopeia was to issue 10M new shares to buy Eos and assume options for an additional 600,000 shares; Pharmacopeia also was to absorb Eos' $44M cash position, but the companies terminated the agreement due to shareholder opposition


Notes:

# This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquisitions of single products or of manufacturing facilities and plants.

For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day prior to the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced.

ND = Not disclosed, reported and/or available

Unless otherwise indicated, shares are traded on Nasdaq; AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; Toronto Stock Exchange

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

*** Conversions of non-U.S. currencies are calculated using the rate on the date the transaction closed, or for pending deals, on the date it was announced.